


**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

What is claimed is

1. (Previously Presented) A compound of formula (I):



or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;


R<sup>1</sup> is SR<sup>6</sup>, SOR<sup>6</sup>, or SO<sub>2</sub>R<sup>6</sup>,

wherein R<sup>6</sup> is a C<sub>3-7</sub>cycloalkyl or C<sub>3-7</sub>cycloalkenyl group;


R<sup>2</sup> and R<sup>3</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halo, phenyl, and C<sub>1-6</sub>haloalkyl;

R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen and C<sub>1-4</sub>alkyl with the proviso that the total number of carbon atoms in R<sup>4</sup> and R<sup>5</sup> is not more than 4;


Ar is a group selected from



(a)




(b)



(c)

and



(d)

wherein  $R^8$  represents hydrogen, halogen,  $-(CH_2)_qOR^{11}$ ,  $-NR^{11}C(O)R^{12}$ ,  $-NR^{11}SO_2R^{12}$ ,  $-SO_2NR^{11}R^{12}$ ,  $-NR^{11}R^{12}$ ,  $-OC(O)R^{13}$  or  $OC(O)NR^{11}R^{12}$ , and  $R^7$  represents hydrogen, halogen, or  $C_{1-4}$  alkyl;

or  $R^8$  represents  $-NHR^{14}$  and  $R^7$  and  $-NHR^{14}$  together form a 5- or 6-membered heterocyclic ring;

$R^9$  represents hydrogen, halogen,  $-OR^{11}$  or  $-NR^{11}R^{12}$ ;

$R^{10}$  represents hydrogen, halogen, halo $C_{1-4}$  alkyl,  $-OR^{11}$ ,  $-NR^{11}R^{12}$ ,  $-OC(O)R^{13}$  or  $OC(O)NR^{11}R^{12}$ ;

$R^{11}$  and  $R^{12}$  each independently represents hydrogen or  $C_{1-4}$  alkyl, or in the groups  $-NR^{11}R^{12}$ ,  $-SO_2NR^{11}R^{12}$  and  $-OC(O)NR^{11}R^{12}$ ,  $R^{11}$  and  $R^{12}$

independently represent hydrogen or C<sub>1-4</sub> alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R<sup>13</sup> represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy or halo C<sub>1-4</sub> alkyl; and

q is zero or an integer from 1 to 4.

2. (Currently Amended) A compound according to Claim 1, wherein R<sup>8</sup> is selected from the group consisting of halogen, -(CH<sub>2</sub>)<sub>q</sub>OR<sup>11</sup>, -NR<sup>11</sup>C(O)R<sup>12</sup>, -NR<sup>11</sup>SO<sub>2</sub>R<sup>12</sup>, -SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, -NR<sup>11</sup>R<sup>12</sup>, -OC(O)R<sup>13</sup>, or OC(O)NR<sup>11</sup>R<sup>12</sup>, and -NHR<sup>14</sup> and R<sup>7</sup> and -NHR<sup>14</sup> together form a 5- or 6- membered heterocyclic ring.


3. (Previously Presented) A compound according to claim 1 wherein R<sup>1</sup> represents -SO<sub>2</sub>R<sup>6</sup>.

4. (Previous Presented) A compound according to claim 1 wherein R<sup>6</sup> represents a C<sub>3-7</sub> cycloalkyl group.


5. (Previously Presented) A compound according to claim 1 wherein R<sup>2</sup> and R<sup>3</sup> each represent hydrogen.

6. (Previously Presented) A compound according to claim 1 wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen and methyl.

7. (Previously Presented) A compound according to claim 1 wherein Ar is selected from a group (a) or (b):




(a)



(b)

8. (Original) A compound of formula (Ia):



(Ia)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;

R<sup>1</sup> is SR<sup>6</sup>, SOR<sup>6</sup>, or SO<sub>2</sub>R<sup>6</sup>,

wherein R<sup>6</sup> is a C<sub>3-7</sub>cycloalkyl or C<sub>3-7</sub>cycloalkenyl group;

R<sup>2</sup> and R<sup>3</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halo, phenyl, and C<sub>1-6</sub>haloalkyl; and

R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen and C<sub>1-4</sub>alkyl with the proviso that the total number of carbon atoms in R<sup>4</sup> and R<sup>5</sup> is not more than 4.

9. (Previously Presented) A compound according to claim 1 wherein m is 5 or

6 and n is 3 or 4.

10. (Currently Amended) A compound selected from the group consisting of:

4-((1*R*)-2-[(6-{4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1*R*)-2-[(6-{4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol (Isomer 1);  
4-((1*R*)-2-[(6-{4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol (Isomer 2);  
4-((1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1*R*)-2-[(6-{4-[4-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1*R*)-2-[(6-{4-[3-(Cyclohexylsulfonyl)phenyl]butyl}oxy)hexyl]amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1*R*)-2-[(6-{4-[3-(3-Cyclopenten-1-ylsulfonyl)phenyl]butyl}oxy)hexyl]amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1*R*)-2-[(6-{5-[3-(Cyclopentylsulfonyl)phenyl]pentyl}oxy)hexyl]amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1*R*)-2-[(7-{3-[3-(Cyclopentylsulfonyl)phenyl]propyl}oxy)heptyl]amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)-5-methylphenyl]butyl}oxy)hexyl]amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
*N*-[5-((1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butyl}oxy)hexyl]amino)-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide;  
4-((1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butyl}oxy)hexyl]amino)-1-hydroxyethyl)-2-fluorophenol;  
6-{2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)pyridin-3-ol};  
5-((1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-8-hydroxy-3,4-dihydroquinolin-2(1*H*)-one;  
5-((1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-hydroxyphenylformamide;

~~and salts thereof~~, solvates thereof, and physiologically functional derivatives thereof.

11. (Previously Presented) A compound according to Claim 10 which is:  
4-((1*R*)-2-((6-(4-(3-(cyclopentylsulfonyl)phenyl)butoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
or a salt, solvate, or physiologically functional derivative thereof.

12. (Previously Presented) A compound according to claim 1 in the form of a salt formed with an arylsulphonic acid.

13. (Currently Amended) A compound according to claim 8 which is selected from the group consisting of:

4-((1*R*)-2-((6-(4-(3-(cyclopentylsulfonyl)phenyl)butoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl) phenol 4-methylbenzenesulfonate;  
4-((1*R*)-2-((6-(4-(3-(cyclopentylsulfonyl)phenyl)butoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol 4-bromobenzene sulfonate;  
4-((1*R*)-2-((6-(4-(3-(cyclopentylsulfonyl)phenyl)butoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol 4-chlorobenzene sulfonate  
4-((1*R*)-2-((6-(4-(3-(cyclopentylsulfonyl)phenyl)butoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol 3-toluene sulfonate;  
4-((1*R*)-2-((6-(4-(3-(cyclopentylsulfonyl)phenyl)butoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl) phenol 4-biphenyl sulfonate; and  
4-((1*R*)-2-((6-(4-(3-(cyclopentylsulfonyl)phenyl)butoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol,naphthalene-2-sulfonate.

14. (Original) A compound according to claim 13 wherein the salt is in crystalline form.

15. (Previously Presented) A method for the prophylaxis or treatment of a clinical condition in a mammal, for which a selective  $\beta_2$ -adrenoreceptor agonist is indicated, which comprises administering a therapeutically effective amount

of a compound according to claim 1 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

16. (Canceled)

17. (Previously Presented) A pharmaceutical formulation comprising a compound according to claim 1 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

18. (Previously Presented) A combination comprising a compound according to claim 1 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and one or more other therapeutic ingredients.

19-21. (Canceled)

22. (Previously Presented) A compound according to claim 1, wherein  $R^{13}$  is a phenyl group.

23. (Previously Presented) A compound according to claim 1, wherein  $R^{13}$  is a naphthyl group.

24. (Previously Presented) A method according to Claim 15, wherein the mammal is a human.

25-34 (Canceled)